Expression of p53, MDM2, and p21 proteins in high-grade cervical intraepithelial neoplasia and relationship to human papillomavirus infection

International Journal of Gynecological Pathology

Volumn 18, Issue 1, 1999, Pages 5-11

  Lie, A Kathrine ^a,b   Skarsvåg, Sølvi ^a   Skomedal, Hanne ^b   Haugen, Olav A ^a   Holm, Ruth ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

CIN; HPV; Immunoreactivity; MDM2; p21; p53

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

EID: 0032909051     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199901000-00002     Document Type: Article

References (42)

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
3. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays 1995;17:501-8.
4. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? J Pathol 1994;172:1-4.
5. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994;186:131-56.
6. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248:76-9.
7. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
9. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993;8:2353-60.
10. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126-32.
11. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
12. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997;15:1179-89.
13. el Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
14. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
15. Jung JM, Bruner JM, Ruan S, et al. Increased levels of p21WAF1/ Cip1 in human brain tumors. Oncogene 1995;11:2021-8.
16. Stefanaki K, Rontogianni D, Kouvidou CH, et al. Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas. Histopathology 1997;30:549-55.
17. Giannikaki E, Kouvidou C, Tzardi M, et al. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. Anticancer Res 1997;17: 2123-7.
18. Valassiadou KE, Stefanaki K, Tzardi M, et al. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res 1997;17:2571-6.
19. Trotter MJ, Tang L, Tron VA. Overexpression of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 in human cutaneous malignant melanoma. J Cutan Pathol 1997;24:265-71.
20. Skomedal H, Kristensen GB, Abeler VM, Borresen-Dale AL, Tropé C, Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 1997;181:158-65.
21. Lie AK, Skjeldestad FE, Hagen B, Haugen OA. Occurrence of human papillomavirus infection in cervical intraepithelial neoplasia. A retrospective histopathological study of 317 cases treated by laser conization. APMIS 1995;103:693-8.
22. Lie AK, Skjeldestad FE, Hagen B, Johannessen E, Skarsvåg S, Haugen OA. Comparision of light microscopy, in situ hybridization and polymerase chain reaction for detection of human papillomavirus in histological tissue of cervical intraepithelial neoplasia. APMIS 1997;105:115-20.
23. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. Lyon: IARC, 1995;1-409.
24. Zehbe I, Rylander E, Edlund K, Wadell G, Wilander E. Detection of human papillomavirus in cervical intra-epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques. Virchows Arch 1996;428:151-7.
25. Holm R, Skomedal H, Helland A, Kristensen G, Borresen AL, Nesland JM. Immunohistochemical analysis of p53 protein over-expression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 1993;169:21-6.
26. Jeffers MD, Richmond J, Farquharson M, McNicol AM. p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. J Clin Pathol 1994;47: 1073-6.
27. Mittal KR, Lin O, Chan W, Goswami S, Demopoulos RI. Cervica squamous dysplasias and carcinomas with immunodetectable p53 frequently contain HPV. Gynecol Oncol 1995;58:289-94.
28. Pollanen R, Soini Y, Vahakangas K, Paakko P, Lehto VP. Aberran p53 protein expression in cervical intra-epithelial neoplasia. His topathology 1993;23:471-4.
29. Ter Harmsel B, van Belkum A, Quint W, et al. p53 and human papilloma virus type 16 in cervical intraepithelial neoplasia and carcinoma. Int J Gynecol Pathol 1995;14:125-33.
30. Vecchione A, Cermele C, Giovagnoli MR, et al. p53 expression and genetic evidence for viral infection in intraepithelial neoplasi of the uterine cervix. Gynecol Oncol 1994;55:343-8.
31. Cooper K, Herrington CS, Evans MF, Gatter KC, McGee JO. p5 antigen in cervical condylomata, intraepithelial neoplasia, and carcinoma: relationship to HPV infection and integration. J Pathol 1993;171:27-34.
32. Garzetti GG, Ciavattini A, Lucarini G, et al. p53 immunostainin and HPV DNA detection by PCR in cervical intraepithelial neoplasia: clinical implications of a combinated evaluation. Antica cer Res 1997;17:555-60.
33. Milde Langosch K, Albrecht K, Joram S, Schlechte H, Giessing I, Loning T. Presence and persistence of HPV infection and p mutation in cancer of the cervix uteri and the vulva. Int J Cancer 1995;63:639-45.
34. Bosari S, Roncalli M, Viale G, Bossi P, Coggi G. p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 1993;169:425-30.
35. Skomedal H, Kristensen GB, Lie AK, Holm R. Aberrent expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclinD1, RB and EGFR in cervical carcinoma. Gynecol Oncol 1998; in press.
36. Piette J, Neel H, Maréchal V. Mdm2: keeping p53 under control. Oncogene 1997;15:1001-10.
37. Ikenberg H, Matthay K, Schmitt B, et al. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer 1995;76:57-66.
38. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997;11:2090-100.
39. Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21 Cip1-mediated inhibition of cdk2. Genes Dev 1997;11:2101-11.
40. Zhang H, Hannon GJ. Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994;8:1750-8.
41. Tieben LM, ter Schegget J, Minnaar RP, et al. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993;42:265-79.
42. Hagmar B, Johansson B, Kalantari M, Petersson Z, Skyldberg B, Walaas L. The incidence of HPV in a Swedish series of invasive cervical carcinoma. Med Oncol Tumor Pharmacother 1992;9: 113-7.